APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Outlook and Growth Opportunities 2026

31 December 2025197 pages

Choose your research edition.

Industry ResearchGranulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocyte-Colony Stimulating Factor (G-CSF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market include Teva, Novartis, Merck, Pfizer, Amgen, SL Pharm, North China Pharmaceutical, Kyowa Kirin and Intas, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocyte-Colony Stimulating Factor (G-CSF) Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market.

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Company

Teva

Novartis

Merck

Pfizer

Amgen

SL Pharm

North China Pharmaceutical

Kyowa Kirin

Intas

Hayao Group

GenSci

Dr. Reddy

Dong-A Socio

Chugai Pharmaceutical

Amoytop

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Type

Filgrastim

Lipefigrastim

Pefigrastim

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Application

Oncology

Blood Disease

Other

Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs key companies, revenue, market share, and recent developments.

3. To split the Granulocyte-Colony Stimulating Factor (G-CSF) Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Granulocyte-Colony Stimulating Factor (G-CSF) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Granulocyte-Colony Stimulating Factor (G-CSF) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs industry.

Chapter 3: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Granulocyte-Colony Stimulating Factor (G-CSF) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends Table 2. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers Table 3. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges Table 4. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints Table 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue Share by Company (2021-2026) Table 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company, Product Type & Application Table 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Filgrastim Table 15. Significant Companies of Lipefigrastim Table 16. Significant Companies of Pefigrastim Table 17. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type (2021-2026) Table 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Oncology Table 23. Significant Companies of Blood Disease Table 24. Significant Companies of Other Table 25. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application (2021-2026) Table 29. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application (2027-2032) Table 30. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Region (2021-2026) Table 33. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Region (2027-2032) Table 35. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Market Share by Country (2027-2032) Table 40. Teva Company Information Table 41. Teva Business Overview Table 42. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 44. Teva Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Company Information Table 51. Merck Business Overview Table 52. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 54. Merck Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 59. Pfizer Recent Development Table 60. Amgen Company Information Table 61. Amgen Business Overview Table 62. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 64. Amgen Recent Development Table 65. SL Pharm Company Information Table 66. SL Pharm Business Overview Table 67. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 69. SL Pharm Recent Development Table 70. North China Pharmaceutical Company Information Table 71. North China Pharmaceutical Business Overview Table 72. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 74. North China Pharmaceutical Recent Development Table 75. Kyowa Kirin Company Information Table 76. Kyowa Kirin Business Overview Table 77. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 79. Kyowa Kirin Recent Development Table 80. Intas Company Information Table 81. Intas Business Overview Table 82. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 84. Intas Recent Development Table 85. Hayao Group Company Information Table 86. Hayao Group Business Overview Table 87. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 89. Hayao Group Recent Development Table 90. GenSci Company Information Table 91. GenSci Business Overview Table 92. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 94. GenSci Recent Development Table 95. Dr. Reddy Company Information Table 96. Dr. Reddy Business Overview Table 97. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 99. Dr. Reddy Recent Development Table 100. Dong-A Socio Company Information Table 101. Dong-A Socio Business Overview Table 102. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 104. Dong-A Socio Recent Development Table 105. Chugai Pharmaceutical Company Information Table 106. Chugai Pharmaceutical Business Overview Table 107. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 109. Chugai Pharmaceutical Recent Development Table 110. Amoytop Company Information Table 111. Amoytop Business Overview Table 112. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio Table 114. Amoytop Recent Development Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Image Figure 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Filgrastim Image Figure 8. Lipefigrastim Image Figure 9. Pefigrastim Image Figure 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type (2021-2032) Figure 13. Oncology Image Figure 14. Blood Disease Image Figure 15. Other Image Figure 16. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim
  • Lipefigrastim
  • Pefigrastim
Applications
  • Oncology
  • Blood Disease
  • Other
Companies covered
  • Teva
  • Novartis
  • Merck
  • Pfizer
  • Amgen
  • SL Pharm
  • North China Pharmaceutical
  • Kyowa Kirin
  • Intas
  • Hayao Group
  • GenSci
  • Dr. Reddy
  • Dong-A Socio
  • Chugai Pharmaceutical
  • Amoytop

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Dynamics
  1. 2.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Trends
  2. 2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Drivers
  3. 2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Opportunities and Challenges
  4. 2.4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Industry Restraints
3 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Company
  1. 3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Ranking (2024-2026)
  4. 3.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Product Type and Application
  6. 3.6 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Type
  1. 4.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Type Introduction
  2. 4.1.1 Filgrastim
  3. 4.1.2 Lipefigrastim
  4. 4.1.3 Pefigrastim
  5. 4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type
  6. 4.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type (2021-2032)
5 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Market by Application
  1. 5.1 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Blood Disease
  4. 5.1.3 Other
  5. 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application
  6. 5.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application (2021-2032)
6 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Regional Value Analysis
  1. 6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Country, 2025 VS 2032
7 Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Country-level Value Analysis
  1. 7.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Amgen
  26. 8.5.1 Amgen Company Information
  27. 8.5.2 Amgen Business Overview
  28. 8.5.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  30. 8.5.5 Amgen Recent Developments
  31. 8.6 SL Pharm
  32. 8.6.1 SL Pharm Company Information
  33. 8.6.2 SL Pharm Business Overview
  34. 8.6.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  36. 8.6.5 SL Pharm Recent Developments
  37. 8.7 North China Pharmaceutical
  38. 8.7.1 North China Pharmaceutical Company Information
  39. 8.7.2 North China Pharmaceutical Business Overview
  40. 8.7.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  42. 8.7.5 North China Pharmaceutical Recent Developments
  43. 8.8 Kyowa Kirin
  44. 8.8.1 Kyowa Kirin Company Information
  45. 8.8.2 Kyowa Kirin Business Overview
  46. 8.8.3 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kyowa Kirin Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  48. 8.8.5 Kyowa Kirin Recent Developments
  49. 8.9 Intas
  50. 8.9.1 Intas Company Information
  51. 8.9.2 Intas Business Overview
  52. 8.9.3 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Intas Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  54. 8.9.5 Intas Recent Developments
  55. 8.10 Hayao Group
  56. 8.10.1 Hayao Group Company Information
  57. 8.10.2 Hayao Group Business Overview
  58. 8.10.3 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Hayao Group Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  60. 8.10.5 Hayao Group Recent Developments
  61. 8.11 GenSci
  62. 8.11.1 GenSci Company Information
  63. 8.11.2 GenSci Business Overview
  64. 8.11.3 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GenSci Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  66. 8.11.5 GenSci Recent Developments
  67. 8.12 Dr. Reddy
  68. 8.12.1 Dr. Reddy Company Information
  69. 8.12.2 Dr. Reddy Business Overview
  70. 8.12.3 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dr. Reddy Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  72. 8.12.5 Dr. Reddy Recent Developments
  73. 8.13 Dong-A Socio
  74. 8.13.1 Dong-A Socio Company Information
  75. 8.13.2 Dong-A Socio Business Overview
  76. 8.13.3 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Dong-A Socio Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  78. 8.13.5 Dong-A Socio Recent Developments
  79. 8.14 Chugai Pharmaceutical
  80. 8.14.1 Chugai Pharmaceutical Company Information
  81. 8.14.2 Chugai Pharmaceutical Business Overview
  82. 8.14.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  84. 8.14.5 Chugai Pharmaceutical Recent Developments
  85. 8.15 Amoytop
  86. 8.15.1 Amoytop Company Information
  87. 8.15.2 Amoytop Business Overview
  88. 8.15.3 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Amoytop Granulocyte-Colony Stimulating Factor (G-CSF) Drugs Product Portfolio
  90. 8.15.5 Amoytop Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst